New Nordic Healthbrands AB Logo

New Nordic Healthbrands AB

Develops and markets herbal supplements & beauty products for natural wellness consumers globally.

NNH | ST

Overview

Corporate Details

ISIN(s):
SE0001838038
LEI:
213800JGTLNSKRD49G44
Country:
Sweden
Address:
SÖDRA FÖRSTADSGATAN 3, 211 43 MALMÖ
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

New Nordic Healthbrands AB is a company specializing in the development, marketing, and sale of herbal-based dietary supplements, natural remedies, and beauty products. Since its establishment in 1990, the company has focused on leveraging its expertise in medicinal plants to create innovative products that address specific health and beauty needs. New Nordic emphasizes scientific validation and quality control, analyzing all ingredients in controlled laboratories to ensure the safety and effectiveness of its offerings. The company markets its distinct brands globally to consumers seeking natural wellness solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all New Nordic Healthbrands AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for New Nordic Healthbrands AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for New Nordic Healthbrands AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-16 Karl Kristian Bergman Jensen Other Sell 5,000 115,000.00 SEK
2025-03-12 Karl Kristian Bergman Jensen Other Sell 5,000 74,900.00 SEK
2025-03-11 Karl Kristian Bergman Jensen Other Sell 5,000 79,500.00 SEK
2025-03-05 Karl Kristian Bergman Jensen Other Sell 5,000 81,250.00 SEK
2025-01-22 Karl Kristian Bergman Jensen Other Sell 5,000 73,300.00 SEK
2025-01-21 Karl Kristian Bergman Jensen Other Sell 5,000 73,500.00 SEK
2025-01-20 Karl Kristian Bergman Jensen Other Sell 5,000 73,500.00 SEK
2024-12-27 Karl Kristian Bergman Jensen Other Sell 5,000 74,050.00 SEK
2024-12-18 Karl Kristian Bergman Jensen Other Sell 5,000 73,300.00 SEK
2024-09-06 Karl Kristian Bergman Jensen Other Sell 4,000 61,960.00 SEK

Peer Companies

Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
Trevi Therapeutics, Inc. Logo
Clinical-stage biopharma developing an oral therapy for chronic cough in IPF and RCC.
United States of America
TRVI
TRINITY BIOTECH PLC Logo
Develops and markets clinical diagnostic test kits and biosensors for labs and point-of-care.
United States of America
TRIB
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD
UCB Logo
UCB
Biopharma firm developing treatments for severe neurological and immunological diseases.
Belgium
UCB
Ultragenyx Pharmaceutical Inc. Logo
Develops and commercializes novel therapies for rare and ultra-rare genetic diseases.
United States of America
RARE
Develops biopharma therapies for endocrinology, ophthalmology, and dermatology needs.
Hong Kong
690
Unicycive Therapeutics, Inc. Logo
A clinical-stage biotech developing novel treatments for kidney diseases, led by oxylanthanum carbonate.
United States of America
UNCY

Talk to a Data Expert

Have a question? We'll get back to you promptly.